Full Text View
Tabular View
No Study Results Posted
Related Studies
Fructose Malabsorption in Northern Norway (FINN)
This study is currently recruiting participants.
Study NCT00555191   Information provided by University Hospital of North Norway
First Received: November 6, 2007   Last Updated: November 7, 2007   History of Changes

November 6, 2007
November 7, 2007
September 2007
 
VAS score og specific abdominal complaints.SGA score of relief related to abdominal complaints. [ Time Frame: 12 weeks ]
Same as current
Complete list of historical versions of study NCT00555191 on ClinicalTrials.gov Archive Site
Estimate sensitivity,specificity,negative and positive predictive value using 50 gm fructose in breath test.Validate questionary for intolerance.Validate VAS in judging changes in abdominal complaint.Examine polymorphism i Glut5 transporter gene. [ Time Frame: 12 weeks ]
Same as current
 
Fructose Malabsorption in Northern Norway
Fructose Malabsorption in Northern Norway. Fructose Malabsorption and Irritable Bowel Syndrome.

Different published studies has shown a possible co-variation between leakage og fructose to the great bowel and exacerbation of irritable bowel syndrome (IBS) symptoms.

The aim of the FINN trial is to study the role of fructose malabsorption in patients with IBS in order to evaluate different diagnostic criteria for fructose malabsorption and at the same time study the effect of diet treatment in this cohort of patients and estimate the prevalence of fructose malabsorption.

 
Phase II, Phase III
Interventional
Treatment, Randomized, Open Label, Parallel Assignment, Efficacy Study
  • Irritable Bowel Syndrome
  • Fructose Malabsorption
Behavioral: diet restriction
  • Active Comparator: PATIENTS IN THIS ARM IS INSTRUCTED IN FRUCTOSEREDUCED DIET
  • No Intervention: these patients use their usual diet
 

*   Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
 
Recruiting
400
January 2011
 

Inclusion Criteria:

  • IBS patients satisfying ROME 2 diagnostic criteria

Exclusion Criteria:

  • Seriously ill
  • Organic abdominal disease
  • Other functional bowel disease
Both
18 Years and older
No
Contact: Leif Kyrre Berg, MD ++47750563235 leif.berg@monet.no
Contact: Jon Florholmen, PhD MD 47029198 jon.florholmen@unn.no
Norway
 
NCT00555191
 
N-136/2006(REK), 136/2006/REK-N, 15567/NSD, Ref 1204 Biobankregisteret
University Hospital of North Norway
  • Nordlandssykehuset HF
  • Hospital of Vefsn Helgelandsykehuset HF
Principal Investigator: Jon Florholmen, MD PhD University Hospital of North Norway, Department of Gastroenterology
University Hospital of North Norway
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP